NCT04897321 2026-04-15
B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)
St. Jude Children's Research Hospital
Phase 1 Recruiting
Clinical Trials
14 trialsNCT07411599 2026-03-12
Dual Administration Of Intraperitoneal And Intravenous TROP2-Directed CAR-NK With TGF-Beta Receptor 2 (TGFBR2) Knock Out (KO) Therapy For Colorectal Cancer-Related Peritoneal Carcinomatosis: A Phase 1/2 Trial ("Chip-CRC Trial")
M.D. Anderson Cancer Center
Phase 1/2 Not yet recruiting
NCT02574728 2026-03-02
AflacST1502
Emory University
Phase 2 Active not recruiting
NCT06782932 2025-12-03
Comparing Neoadjuvant/Adjuvant GVAX vs a mKRASvax Given With Anti-PD-1 and Anti-CD137 for Surgically Resectable Pancreatic Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1/2 Recruiting
NCT05035407 2025-12-02
T Cell Receptor Gene Therapy Targeting KK-LC-1 for Gastric, Breast, Cervical, Lung and Other KK-LC-1 Positive Epithelial Cancers
National Institutes of Health Clinical Center (CC)
Phase 1 Terminated
NCT05141474 2024-11-07
NEXTGENTIL-ACT
Vall d'Hebron Institute of Oncology
Phase EARLY_PHASE1 Recruiting
NCT03190265 2024-08-07
Study of CRS-207, Nivolumab, and Ipilimumab With or Without GVAX Pancreas Vaccine (With Cy) in Patients With Pancreatic Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT06013111 2024-02-21
An Exploratory Clinical Study Evaluating the Safety and Efficacy of Anti-CEA-CAR-T Cells Injection in Patients With CEA+ Locally Advanced and/or Metastatic Solid Tumors
China Medical University, China
Phase 1 Recruiting
NCT04596033 2022-07-15
TiTAN-1: Safety, Proliferation and Persistence of GEN-011 Autologous Cell Therapy
Genocea Biosciences, Inc.
Phase 1 Terminated
NCT00887536 2022-04-20
A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
NSABP Foundation Inc
Phase 3 Completed
NCT01554371 2021-02-03
Eribulin in Combination With Cyclophosphamide in Patients With Solid Tumor Malignancies
University of California, San Francisco
Phase 1/2 Completed
NCT01507103 2017-01-13
SPRINT
Merck KGaA, Darmstadt, Germany
Phase 2 Completed
NCT00157196 2015-08-18
Safety Study of Tecemotide (L-BLP25) in Non-Small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease
Merck KGaA, Darmstadt, Germany
Phase 2 Completed
NCT01175772 2015-06-23
Maintenance Treatment for Ovarian Carcinoma in Remission by an Antiangiogenic Treatment Strategy
HaEmek Medical Center, Israel
Phase 2 Terminated